OBJECTIVETo throw light on the superiority of the anti-angiogenesis activity of endostatin (ES) derivatives by reviewing the recent progress in the field of ES molecular structure modification.

DATA SOURCESThe data used in this article were mainly from PubMed with relevant English articles published from 1971 to May 2008. The search terms were "endostatin" and "angiothesis".

STUDY SELECTIONArticles involved in the ES molecular structure modification and the original milestone articles were selected.

RESULTSA number of ES derivatives were designed and studied to improve its clinical relevance. The modified ES with polyethylene glycol (PEG), low molecular weight heparin (LMWH) and IgG Fc domain extended the circulation half-life. Meanwhile the recombinant ESs showed more potent anti-tumor activity than native ES in mouse xenografts. Mutated ES also changed its anti-angiogenesis activity.

CONCLUSIONSThe anti-angiogenesis treatment remains a promising tumor therapeutic strategy. New ES derivatives would be a good choice to meet the future challenge on clinical application of ES.

Angiogenesis Inhibitors ; pharmacokinetics ; therapeutic use ; Animals ; Endostatins ; pharmacokinetics ; therapeutic use ; Humans ; Neovascularization, Pathologic ; drug therapy

Antiangiogenic therapy has entered clinical practice and shown good clinical benefits. However, no validated biomarker has been confirmed to be useful for screening patients who will respond to antiangiogenic therapy. Many systemic, circulating, tissue and imaging biomarkers are emerging and need to be prospectively validated.
Angiogenesis Inhibitors ; therapeutic use ; Antineoplastic Agents ; therapeutic use ; Biomarkers ; Humans ; Neoplasms ; drug therapy

Angiogenesis Inhibitors ; therapeutic use ; Endostatins ; therapeutic use ; Histiocytic Sarcoma ; drug therapy ; Humans ; Male ; Middle Aged ; Recombinant Proteins ; therapeutic use

Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Advanced lung cancer patients, no matter different groups or different stages of the disease, are benefited from anti-angiogenes. In this paper, based on the clinical status and unsolved problems, combined with the latest clinical and translational research data, we reviewed the current anti-angiogenesis treatment of lung cancer.
.
Angiogenesis Inhibitors/therapeutic use* ; Humans ; Immunotherapy ; Lung Neoplasms/pathology* ; Molecular Targeted Therapy ; Neovascularization, Pathologic/drug therapy*

BACKGROUNDWhat benefits and toxicities patients acquire from the use of bevacizumab combined with firstline chemotherapy remains controversial. This study was performed to evaluate the efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer (mCRC).

METHODSSeveral databases, including PubMed, Embase, and Cochrane Library, were searched up to April 30, 2013. Eligible studies were only randomized, controlled trials (RCTs) with a direct comparison between mCRC patients treated with and without bevacizumab. Overall risk ratio (RR), hazard ratio (HR), odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed or random-effects models depending on the heterogeneity of the included trials.

RESULTSSix RCTs, including 1582 patients in chemotherapy plus bevacizumab group and 1484 patients in chemotherapyalone group, were included. Overall, the addition of bevacizumab to first-line chemotherapy increased overall response rate (ORR) by 4.5%, prolonged both progression-free survival (PFS) and overall survival (OS), and increased the rate of total Grades 3 or 4 adverse events (G3/4AEs) by 6.9%. Significant differences were found in ORR (RR = 1.22 (95% CI 1.01-1.46), P = 0.03), PFS (HR = 0.60 (95% CI 0.47-0.77), P < 0.0001), OS (HR = 0.83 (95% CI 0.70-0.97), P = 0.02), and any G3/4AEs (OR = 1.56 (95% CI 1.29-1.89), P < 0.00001).

CONCLUSIONBevacizumab is a valuable addition to the current first-line chemotherapy regimens used in patients with mCRC, because of conferring a significant improvement in ORR, PFS, and OS, even though it increased adverse events.

Angiogenesis Inhibitors ; therapeutic use ; Antibodies, Monoclonal, Humanized ; therapeutic use ; Bevacizumab ; Colorectal Neoplasms ; drug therapy ; Humans ; Odds Ratio

Arsenic trioxide has been used to treat lymphoma experimentally since it was used to treat acute promyelocytic leukemia successfully. Massive works in this field have been done throughout the world. It was found that arsenic trioxide exerted an anti-lymphomatic effect via many pathways, and many substances could increase or reduce this effect. Arsenic trioxide can be used to treat relapsed and refractory lymphomas resistant to other chemotherapies with some therapeutic effects and limited side effects, which indicates that arsenic trioxide is a new potential drug for lymphoma. This article is an overview about these foundational and clinical studies.
Angiogenesis Inhibitors ; therapeutic use ; Antineoplastic Agents ; therapeutic use ; Apoptosis ; drug effects ; Arsenicals ; therapeutic use ; Humans ; Lymphoma ; drug therapy ; Oxides ; therapeutic use

Molecule-targeting agents inhibit the proliferation of tumor cells by the molecular biological differences between tumor cells and normal cells, and finally kill tumor cells. This article introduces several molecule-targeting agents that are currently under clinical trials now.
Angiogenesis Inhibitors ; therapeutic use ; Antibodies, Monoclonal ; therapeutic use ; Antineoplastic Agents ; therapeutic use ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; Erlotinib Hydrochloride ; Humans ; Lung Neoplasms ; drug therapy ; Protein-Tyrosine Kinases ; antagonists & inhibitors ; Quinazolines ; therapeutic use ; Receptor, Epidermal Growth Factor ; antagonists & inhibitors

Molecular-targeted therapy is a newly developed approach for cancer therapy. With the advantages of lower side effects and higher performance, this approach has become a critical focus of cancer research. There are various molecules that can be treated as therapeutic targets for cancer. These molecules are located in different compartments of cancer cells, such as the cell membrane, cytoplasm, nuclei, and extracellular matrix. In this review, we mainly discussed the current progress in molecular-targeted therapy for cancers and the development of new drugs in this field.
Angiogenesis Inhibitors ; therapeutic use ; Antibodies, Monoclonal ; therapeutic use ; Antineoplastic Agents ; therapeutic use ; Humans ; Molecular Targeted Therapy ; methods ; Neoplasms ; drug therapy ; metabolism ; Neovascularization, Pathologic ; drug therapy

OBJECTIVETo study the effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice.

METHODSMetastatic model simulating human gastric cancer was established by orthotopic implantation of histologically intact human tumor tissue into the gastric wall of SCID mice. Rg3 was administered by gastric perfusion at doses of 0, 2.5, 5.0, 10.0 mg/kg every day for 6 weeks 1 week after tumor implantation. One week after last administration, the mice were killed and their tumor weight was measured and the presence of metastasis recorded. Intratumoral microvessel density was examined by immunohistochemical staining with anti-CD31 monoclonal antibody.

RESULTSCompared to the untreated controls, the growth of the orthotopically implanted tumor was significantly reduced in weight in mice treated with Rg3 with an inhibition rate of 52.3%, 63.3% and 71.6% at doses of 2.5, 5.0, 10.0 mg/kg, respectively. Tumor metastasis to the liver and peritoneum was also significantly inhibited in a dose-dependent manner. Decreased intratumoral microvessel density was noted in the treated mice.

CONCLUSIONAngiogenesis inhibitor Rg3 has strong inhibitory effect on tumor growth and metastasis of human gastric cancer in SCID mice.

Angiogenesis Inhibitors ; therapeutic use ; Animals ; Antineoplastic Agents ; therapeutic use ; Female ; Ginsenosides ; therapeutic use ; Humans ; Mice ; Mice, SCID ; Neoplasm Metastasis ; Stomach Neoplasms ; blood supply ; drug therapy ; pathology

Angiogenesis Inhibitors ; therapeutic use ; Animals ; Carcinoma, Hepatocellular ; therapy ; Endostatins ; therapeutic use ; Humans ; Liver Neoplasms ; therapy ; Neovascularization, Pathologic ; Vascular Endothelial Growth Factor A ; therapeutic use